Again, in a phase 2 study of 48 patients with CD30+ cutaneous T-cell lymphoma, brentuximab vedotin produced a high overall tumour response rate of 73% but the responses did not correlate with tumour CD30 expression; even patients with low-level expression (<10%) achieved 50% partial response rate (Duvic et al, 2015). Here, TNFRSF8 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.